What we still don't know about vascularized composite allotransplantation (VCA) outcomes and quality of life measurements

Fay Bound Alberti, Matthew Ridley, Emily Herrington, James L. Benedict, Sarah Hall

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Vascularized composite allotransplants (VCA) are the only organ transplants purported to be conducted principally to improve quality of life (QOL), rather than to extend or save life - hence they are described as “life-enhancing” (or “life-rescuing”). This is in contrast to “life-extending” solid organ transplantation (SOT). Yet despite more than 20 years of VCA practice (1997-present), little is known about the actual “life-enhancing” impact(s) of VCA on the patient or their families. This article presents an overview of the state of the VCA field and what we still don't know about VCA outcomes, specifically focussing on face and hand transplants as both visible, emotional, and communicative organs.

The current measurement of QOL in VCA is insufficient, both conceptually and analytically. It is also, critically, conducted without reference to patient-reported outcomes, or the experiences of family and carers. Drawing on published research in VCA and SOT, as well as preliminary, anecdotal VCA patient interview research, this paper highlights how and why the QOL practices in the field of VCA are not fit for purpose and proposes new ways of analysing QOL. In conclusion, it outlines what needs to happen for the VCA field to move forward positively, and with patients and their families more central to VCA practice and research.
Original languageEnglish
Article number100708
JournalTRANSPLANTATION REVIEWS
Volume36
Issue number3
Early online date26 May 2022
DOIs
Publication statusPublished - 1 Jul 2022

Fingerprint

Dive into the research topics of 'What we still don't know about vascularized composite allotransplantation (VCA) outcomes and quality of life measurements'. Together they form a unique fingerprint.

Cite this